A structured summary of a study protocol for a randomised controlled trial of Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R) has been published in the BioMed Central Journal.
The TACTIC programme emerged from the hypothesis that immunomodulation would be likely to reduce the severity of COVID-19-related disease – a model supported by results from the RECOVERY trial indicating that a corticosteroid, dexamethasone, reduces mortality in patients with severe disease. TACTIC has been designed to assess selected medications which modify aspects of the immune response. These medications have been chosen by a consortium of clinicians and clinician-scientists with expertise in the treatment of immune-mediated disease and it is hoped that they will further reduce morbidity and mortality from COVID-19-related disease.
The TACTIC-R trial, using licensed drugs ‘Repurposed’ for the treatment of COVID-19-related disease, launched in Cambridge on 7th May 2020. The trial has three arms in a parallel-group, randomised design.
The treatments currently being tested are:
Baricitinib – a drug routinely used to treat rheumatoid arthritis, which reduces soluble signals in the immune system called cytokines. It is hypothesised that this will reduce the damaging inflammatory drive in COVID-19-related disease.
Ravulizumab – a drug used to treat a form of anaemia caused by the person’s immune system; this blocks activation of a cascade of soluble molecules which amplify inflammatory signals and, ultimately, destroy cells.
Standard of Care – itself evolving as data emerge from other clinical trials.
For more information visit: CamCovidTrials
Published July 8, 2020
An Addenbrooke’s trial is rolling out to hospitals across the UK to see if a drug used to treat tapeworm can give high-risk kidney patients extra protection…
UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH)…
Two new clinical trials to develop treatments to prevent people catching (coronavirus) COVID-19 are to launch in the UK.